• Fri. Nov 22nd, 2024

Vandana Singh

  • Home
  • Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly – Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly – Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

[ad_1] Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc PFE and BioNTech SE BNTX reduced hospitalizations among older patients. The study has not yet been peer-reviewed. Data…

Why Graphite Bio (GRPH) Shares Are Plunging Today – Graphite Bio (NASDAQ:GRPH)

[ad_1] Graphite Bio Inc GRPH voluntarily paused the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) following a serious adverse event in the first patient dosed with…

Why Novocure (NVCR) Stock Is Soaring Today – NovoCure (NASDAQ:NVCR)

[ad_1] Zai Lab Limited ZLAB and Novocure Ltd NVCR announced that the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. …

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca – GSK (NYSE:GSK)

[ad_1] GSK plc GSK chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a ‘bidding…

Novavax Kickstarts Phase 2 Trial For COVID-19-Flu Combo, Stand-Alone Flu Vaccine Candidates – Novavax (NASDAQ:NVAX)

[ad_1] Novavax Inc NVAX has initiated a Phase 2 trial for its COVID-19-Influenza Combination (CIC) and influenza stand-alone vaccine candidates.  The dose-confirming trial will evaluate the safety and effectiveness (immunogenicity)…